Pr Philippe Moreau
- Spécialité
- Hématologue, expert myélome multiple
- Hôpital
- Centre Hospitalier Universitaire de Nantes
- Derniers articles
-
- Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load. (18 déc. 2025)
- Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. (10 déc. 2025)
- Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent. (28 nov. 2025)
- Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network. (25 nov. 2025)
- Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies. (31 oct. 2025)